Online inquiry

IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8718MR)

This product GTTS-WQ8718MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets F3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001178096.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2152
UniProt ID P13726
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8718MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9370MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ15932MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ8683MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ12380MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA NEOD-001
GTTS-WQ576MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 62-71-3
GTTS-WQ1263MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-414
GTTS-WQ13438MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ9229MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-107
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW